EGFR and head and neck squamous cell carcinoma: Combining gefitinib with CmpdA (inhibitor of I-Kappa-B kinase-beta (IKKβ) regulatory subunit of NF-κB pathway) [123] or Bay117085 (IκBα kinase and NF-κB inhibitor) [124] in pre-clinical models suggests that this EGFR-NF-κB axis inhibition is an excellent alternative approach for HNSCC treatment.